




RealRate

PHARMACEUTICAL 2022

Dyne Therapeutics Inc
Rank 145 of 471



The relative strengths and weaknesses of Dyne Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dyne Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Dyne Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 349%, being 74% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	382,392
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,723
Liabilities, Non-Current	28,743
Other Assets	38,593
Other Compr. Net Income	-242
Other Expenses	0
Other Liabilities	0
Other Net Income	734
Other Revenues	0
Property and Equipment	4,678
Research and Development	121,308
Selling, General and Administrative Expense	28,717

Output Variable	Value in 1000 USD
Assets	425,663
Liabilities	57,466
Expenses	150,025
Revenues	0
Stockholders Equity	368,197
Net Income	-149,291
Comprehensive Net Income	-149,412
BaseVar	317,065
ECR before Limited Liability	270%
Economic Capital Ratio	349%